Retatrutide Glossary: Triple Agonist Terms

Understanding retatrutide means understanding a new vocabulary of medical and pharmacological terms. This glossary defines every key term patients encounter when researching the triple agonist, organized alphabetically for quick reference (Jastreboff et al., NEJM 2023).

A-D

Agonist: A substance that activates a receptor, triggering a biological response. Retatrutide is an agonist at three receptors (GLP-1, GIP, glucagon).

Anorexigenic: Appetite-suppressing. Retatrutide has strong anorexigenic effects through GLP-1 and central nervous system pathways.

Area Postrema: A brainstem region involved in nausea. GLP-1 receptors here mediate the nausea associated with GLP-1 medications.

Beta-cell: Insulin-producing cells in the pancreas. GLP-1 and GIP protect and stimulate beta-cells.

BMI (Body Mass Index): Weight in kg divided by height in meters squared. BMI 30+ is classified as obesity; 25-29.9 as overweight.

Calcitonin: A hormone from thyroid C-cells. Elevated calcitonin can indicate medullary thyroid carcinoma. Monitored in some GLP-1 patients.

C-cell: Thyroid cells that produce calcitonin. GLP-1 medications caused C-cell tumors in rodents (but not confirmed in humans).

Dose escalation: Gradually increasing medication dose over time. Retatrutide typically escalates from 1mg to 12mg over 16-20 weeks.

Dysesthesia: An abnormal, unpleasant sensation such as tingling, burning, or prickling. A side effect relatively unique to retatrutide, likely from glucagon receptor activation on peripheral nerves.

E-G

Eli Lilly: The pharmaceutical company developing retatrutide. Also makes tirzepatide (Mounjaro/Zepbound).

Gastric emptying (delayed): Food leaving the stomach more slowly than normal. A GLP-1 effect that contributes to fullness and appetite reduction.

GIP (Glucose-dependent Insulinotropic Polypeptide): An incretin hormone that enhances insulin release and may improve fat metabolism. Retatrutide activates the GIP receptor.

GLP-1 (Glucagon-Like Peptide-1): An incretin hormone that suppresses appetite, stimulates insulin, and slows gastric emptying. The primary target of semaglutide and a key target of retatrutide.

Glucagon: A pancreatic hormone that raises blood sugar and promotes fat oxidation. Retatrutide uniquely activates the glucagon receptor, increasing energy expenditure.

Gluconeogenesis: The liver's production of glucose from non-carbohydrate sources. Glucagon stimulates gluconeogenesis.

H-M

HbA1c: Hemoglobin A1c; a blood test reflecting average blood sugar over 2-3 months. Normal is below 5.7%; diabetes is 6.5%+.

Hypothalamus: A brain region that regulates appetite, body temperature, and hormone release. GLP-1 receptors in the hypothalamus mediate appetite suppression.

Incretin: A gut hormone released after eating that stimulates insulin. GLP-1 and GIP are the two main incretins. Retatrutide is an incretin-based therapy.

Lipodystrophy: Abnormal fat distribution at injection sites from repeated injection in the same location. Prevented by rotating injection sites.

LY3437943: Retatrutide's internal compound number at Eli Lilly.

MASH: Metabolic dysfunction-Associated Steatohepatitis (formerly NASH). Fatty liver disease with inflammation. Retatrutide's glucagon component may be uniquely beneficial.

MTC (Medullary Thyroid Carcinoma): A rare thyroid cancer arising from C-cells. Personal or family history is a contraindication for GLP-1 medications.

MEN2 (Multiple Endocrine Neoplasia type 2): A genetic syndrome that includes MTC. Contraindication for GLP-1 medications.

N-S

NDA (New Drug Application): The formal submission to the FDA for drug approval. Eli Lilly will submit an NDA after Phase 3 completion.

Pancreatitis: Inflammation of the pancreas. A rare but serious risk with GLP-1 medications. Symptoms include severe abdominal pain radiating to the back.

Peptide: A short chain of amino acids. Retatrutide is a peptide that must be injected (not taken orally) because stomach acid would destroy it.

Pharmacokinetics: How the body absorbs, distributes, metabolizes, and excretes a drug. Retatrutide's pharmacokinetics support once-weekly dosing.

Subcutaneous: Under the skin. Retatrutide is a subcutaneous injection into the fat layer beneath the skin.

T-Z

Telogen effluvium: Stress-induced temporary hair shedding. Common with rapid weight loss from any cause, including GLP-1 medications.

Thermogenesis: Heat production by the body, which burns calories. Glucagon receptor activation increases thermogenesis, a unique benefit of retatrutide.

Titration: Gradually adjusting a drug dose. Retatrutide titration typically takes 16-20 weeks.

Triple agonist: A medication that activates three different receptors. Retatrutide is the first triple agonist (GLP-1/GIP/glucagon) for obesity.

TRIUMPH: The name of retatrutide's Phase 3 clinical trial program.

GLP-1 Treatment With Expert Guidance

Trimi offers compounded semaglutide ($99/month) and compounded tirzepatide ($125/month) with medical teams who explain every aspect of your treatment in plain language. Learn how Trimi works.

Frequently Asked Questions

What makes a triple agonist different from a dual agonist?

A dual agonist (tirzepatide) targets two receptors. A triple agonist (retatrutide) adds glucagon receptor activation, which uniquely increases energy expenditure and fat oxidation. This additional mechanism may explain retatrutide's greater weight loss.

What does "investigational" mean?

An investigational drug is one being studied in clinical trials but not yet approved by the FDA for commercial sale. Retatrutide is investigational, meaning its safety and efficacy are still being formally evaluated.

What is an incretin?

Incretins are gut hormones released after eating that enhance insulin secretion. GLP-1 and GIP are the two main incretins. Incretin-based therapies like retatrutide leverage these natural hormone pathways.

Why does retatrutide need to be injected?

As a peptide, retatrutide would be destroyed by stomach acid if taken orally. Subcutaneous injection delivers it directly into the bloodstream intact.